Secretion of hepatocyte growth factor and vascular endothelial growth factor during uveal melanoma-monocyte in vitro interactions. 2005

Jonathan Cools-Lartigue, and Jean Claude Marshall, and Amanda L Caissie, and Vinicius S Saraiva, and Miguel N Burnier
3775 University Lyman Duff, Rm 216, Montreal, QC, H3A 2B4, Canada. Jonathan.Cools-Lartigue@mail.mcgill.ca

Host-tumour interactions in uveal melanoma, and their involvement in the biological events leading to metastasis and eventually mortality, are not well understood. It is known that uveal melanoma disseminates predominantly via a haematogenous route with metastasis developing primarily in the liver. Therefore, cytokines involved in angiogenesis, such as vascular endothelial growth factor (VEGF), and those expressed in large quantities within the liver, such as hepatocyte growth factor (HGF), are of particular interest in uveal melanoma research. This study investigated the levels of HGF and VEGF in monocyte and uveal melanoma-conditioned medium. Five human uveal melanoma cell lines and one monocyte cell line were seeded in six-well plates. After 18 h, melanoma-conditioned medium (MCM) was placed on the monocyte cell line and monocyte-conditioned medium (MoCM) was placed on each uveal melanoma cell line. Tumour cells and monocytes incubated in fresh, as opposed to conditioned, medium after 18 h were used as controls. VEGF and HGF levels were determined by immunoassay prior to media transfer and 6, 12, 24 and 36 h thereafter. Both cytokines showed an upregulation of expression from all cells after incubation in conditioned medium. 28SC incubated in MCM expressed higher levels of the given cytokines than did uveal melanoma cells incubated in MoCM. In addition, each cell line exhibited a distinct pattern of expression, with individual cell lines exhibiting different peak levels of cytokine production at different time points. These results offer insight into the upregulation of VEGF and HGF, which may play a role in tumour-host cell interactions.

UI MeSH Term Description Entries
D008545 Melanoma A malignant neoplasm derived from cells that are capable of forming melanin, which may occur in the skin of any part of the body, in the eye, or, rarely, in the mucous membranes of the genitalia, anus, oral cavity, or other sites. It occurs mostly in adults and may originate de novo or from a pigmented nevus or malignant lentigo. Melanomas frequently metastasize widely, and the regional lymph nodes, liver, lungs, and brain are likely to be involved. The incidence of malignant skin melanomas is rising rapidly in all parts of the world. (Stedman, 25th ed; from Rook et al., Textbook of Dermatology, 4th ed, p2445) Malignant Melanoma,Malignant Melanomas,Melanoma, Malignant,Melanomas,Melanomas, Malignant
D009000 Monocytes Large, phagocytic mononuclear leukocytes produced in the vertebrate BONE MARROW and released into the BLOOD; contain a large, oval or somewhat indented nucleus surrounded by voluminous cytoplasm and numerous organelles. Monocyte
D002450 Cell Communication Any of several ways in which living cells of an organism communicate with one another, whether by direct contact between cells or by means of chemical signals carried by neurotransmitter substances, hormones, and cyclic AMP. Cell Interaction,Cell-to-Cell Interaction,Cell Communications,Cell Interactions,Cell to Cell Interaction,Cell-to-Cell Interactions,Communication, Cell,Communications, Cell,Interaction, Cell,Interaction, Cell-to-Cell,Interactions, Cell,Interactions, Cell-to-Cell
D002460 Cell Line Established cell cultures that have the potential to propagate indefinitely. Cell Lines,Line, Cell,Lines, Cell
D004797 Enzyme-Linked Immunosorbent Assay An immunoassay utilizing an antibody labeled with an enzyme marker such as horseradish peroxidase. While either the enzyme or the antibody is bound to an immunosorbent substrate, they both retain their biologic activity; the change in enzyme activity as a result of the enzyme-antibody-antigen reaction is proportional to the concentration of the antigen and can be measured spectrophotometrically or with the naked eye. Many variations of the method have been developed. ELISA,Assay, Enzyme-Linked Immunosorbent,Assays, Enzyme-Linked Immunosorbent,Enzyme Linked Immunosorbent Assay,Enzyme-Linked Immunosorbent Assays,Immunosorbent Assay, Enzyme-Linked,Immunosorbent Assays, Enzyme-Linked
D006801 Humans Members of the species Homo sapiens. Homo sapiens,Man (Taxonomy),Human,Man, Modern,Modern Man
D000818 Animals Unicellular or multicellular, heterotrophic organisms, that have sensation and the power of voluntary movement. Under the older five kingdom paradigm, Animalia was one of the kingdoms. Under the modern three domain model, Animalia represents one of the many groups in the domain EUKARYOTA. Animal,Metazoa,Animalia
D014604 Uveal Neoplasms Tumors or cancer of the UVEA. Neoplasm, Uveal,Neoplasms, Uveal,Uveal Neoplasm
D015854 Up-Regulation A positive regulatory effect on physiological processes at the molecular, cellular, or systemic level. At the molecular level, the major regulatory sites include membrane receptors, genes (GENE EXPRESSION REGULATION), mRNAs (RNA, MESSENGER), and proteins. Receptor Up-Regulation,Upregulation,Up-Regulation (Physiology),Up Regulation
D017077 Culture Media, Conditioned Culture media containing biologically active components obtained from previously cultured cells or tissues that have released into the media substances affecting certain cell functions (e.g., growth, lysis). Conditioned Culture Media,Conditioned Culture Medium,Conditioned Media,Conditioned Medium,Culture Medium, Conditioned,Media, Conditioned,Medium, Conditioned

Related Publications

Jonathan Cools-Lartigue, and Jean Claude Marshall, and Amanda L Caissie, and Vinicius S Saraiva, and Miguel N Burnier
October 2006, Archives of ophthalmology (Chicago, Ill. : 1960),
Jonathan Cools-Lartigue, and Jean Claude Marshall, and Amanda L Caissie, and Vinicius S Saraiva, and Miguel N Burnier
January 2013, Ecancermedicalscience,
Jonathan Cools-Lartigue, and Jean Claude Marshall, and Amanda L Caissie, and Vinicius S Saraiva, and Miguel N Burnier
January 2004, Klinika oczna,
Jonathan Cools-Lartigue, and Jean Claude Marshall, and Amanda L Caissie, and Vinicius S Saraiva, and Miguel N Burnier
July 2000, The British journal of ophthalmology,
Jonathan Cools-Lartigue, and Jean Claude Marshall, and Amanda L Caissie, and Vinicius S Saraiva, and Miguel N Burnier
March 2001, The American journal of pathology,
Jonathan Cools-Lartigue, and Jean Claude Marshall, and Amanda L Caissie, and Vinicius S Saraiva, and Miguel N Burnier
May 2014, Molecular and clinical oncology,
Jonathan Cools-Lartigue, and Jean Claude Marshall, and Amanda L Caissie, and Vinicius S Saraiva, and Miguel N Burnier
March 1998, British journal of cancer,
Jonathan Cools-Lartigue, and Jean Claude Marshall, and Amanda L Caissie, and Vinicius S Saraiva, and Miguel N Burnier
November 1996, Experimental eye research,
Jonathan Cools-Lartigue, and Jean Claude Marshall, and Amanda L Caissie, and Vinicius S Saraiva, and Miguel N Burnier
July 2009, Cancer prevention research (Philadelphia, Pa.),
Jonathan Cools-Lartigue, and Jean Claude Marshall, and Amanda L Caissie, and Vinicius S Saraiva, and Miguel N Burnier
June 2003, Coronary artery disease,
Copied contents to your clipboard!